SCH-50911

SCH-50911
Names
	Preferred IUPAC name 2-[(2S)-5,5-Dimethylmorpholin-2-yl]acetic acid
Identifiers
CAS Number	160415-07-6 ;
3D model (JSmol)	Interactive image;
ChemSpider	4470917 ;
IUPHAR/BPS	1075;
MeSH	SCH-50911
PubChem CID	5311429;
UNII	Q5MMG73452 ;
CompTox Dashboard (EPA)	DTXSID0045670 ;
	InChI InChI=1S/C8H15NO3/c1-8(2)5-12-6(4-9-8)3-7(10)11/h6,9H,3-5H2,1-2H3,(H,10,11)/t6-/m0/s1 Key: SEYCKMQSPUVYEF-LURJTMIESA-N ; InChI=1/C8H15NO3/c1-8(2)5-12-6(4-9-8)3-7(10)11/h6,9H,3-5H2,1-2H3,(H,10,11)/t6-/m0/s1 Key: SEYCKMQSPUVYEF-LURJTMIEBV;
	SMILES O=C(O)C[C@@H]1OCC(NC1)(C)C;
Properties
Chemical formula	C8H15NO3
Molar mass	173.21 g·mol−1
Melting point	154.5 to 157 °C (310.1 to 314.6 °F; 427.6 to 430.1 K) (hydrochloride)
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	(what is ?)
	Infobox references

SCH-50911 is a selective GABA_B antagonist.^[1] Its main applications are in pharmacology research.

SCH-50911 also acts as an anticonvulsant under normal conditions. SCH-50911 induces acute withdrawal syndrome in GHB-dependent rats, similar to the delirium tremens seen in human alcohol withdrawal, and can precipitate convulsions in GHB-dependent animals.^[2]

References[]

^ Blythin DJ, Kuo SC, Shue HJ, McPhail AT, Chapman RW, Kreutner W, et al. (July 1996). "Substituted morpholine-2S-acetic acid derivatives: Sch 50911 and related compounds as novel GABAB antagonists". Bioorganic & Medicinal Chemistry Letters. 6 (13): 1529–34. doi:10.1016/S0960-894X(96)00267-3.
^ Quang LS, Colombo G, Lobina C, Maccioni P, Orru A, Gessa GL, et al. (August 2006). "Evaluation for the withdrawal syndrome from gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines". Annals of the New York Academy of Sciences. 1074: 545–58. doi:10.1196/annals.1369.055. PMID 17105952.

[1] Blythin DJ, Kuo SC, Shue HJ, McPhail AT, Chapman RW, Kreutner W, et al. (July 1996). "Substituted morpholine-2S-acetic acid derivatives: Sch 50911 and related compounds as novel GABAB antagonists". Bioorganic & Medicinal Chemistry Letters. 6 (13): 1529–34. doi:10.1016/S0960-894X(96)00267-3.

[pmid17105952-2] Quang LS, Colombo G, Lobina C, Maccioni P, Orru A, Gessa GL, et al. (August 2006). "Evaluation for the withdrawal syndrome from gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines". Annals of the New York Academy of Sciences. 1074: 545–58. doi:10.1196/annals.1369.055. PMID 17105952.

[1]

[2]